Results 91 to 100 of about 11,074 (164)

Sustained Complete Response to Brigatinib in a Young Patient With ALK-Positive NSCLC Harboring I1171N Mutation Post-Alectinib Resistance

Case Reports in Oncological Medicine
ALK-rearranged non–small cell lung cancer (NSCLC) represents a paradigm of precision oncology, but acquired resistance to second-generation ALK tyrosine kinase inhibitors (TKIs) such as alectinib remains inevitable. We report a young, nonsmoker male with
Akhil Kapoor, Ajay Kumar Singh, Mahesh Chaudhary, Anuj Gupta, Bipinesh Sansar, Bal Krishna Mishra, Shashikant Patne, Arvind Suresh   +7 more
doaj   +1 more source

Supplementary Figures S1-S5 from Alectinib Shows Potent Antitumor Activity against RET-Rearranged Non–Small Cell Lung Cancer

, 2014
Supplementary Figures S1-S5. Figure S1: Kinase selectivity of alectinib, vandetanib, cabozantinib, sorafenib, sunitinib, and ponatinib against several kinases including RET.
Toshiyuki Tsukaguchi (2167447), Miyuki Yoshida (3225339), Hiroshi Sakamoto (12380), Tatsushi Kodama (15068877), Osamu Kondoh (14979276), Yasuko Satoh (14937048), Yoshiaki Watanabe (5477540)   +6 more
core   +1 more source

CNS Activity of Alectinib in Advanced ALK-Rearranged NSCLC: A Retrospective Review

, 2018
Purpose: Central nervous system (CNS) metastases are a significant contributor to morbidity and mortality in ALK-rearranged non-small cell lung cancer (NSCLC). While the ability ofalectinib is known to have excellent CNS activity alectinib to control CNS
Jiang, Ginger
core   +2 more sources

Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial

, 2022
Background: Alectinib, a highly selective next generation ALK-inhibitor, has exhibited potent anti-tumour activity in RET-rearranged NSCLC in the preclinical stage.
Dingemans, A.-M.C., Cobo, M., Molina-Vila, M.A., Cuffe, S., Ruepp, B., Felip, E., Passiglia, F., Britschgi, C., Smit, E.F., de Marinis, F., Provencio, M., Peters, S., Stahel, R., Viteri, S., Andriakopoulou, C., Merkelbach-Bruse, S., Massuti, B., Dafni, U., Wolf, J., Berghmans, T., Kammler, R., Roschitzki-Voser, H.   +21 more
core  

Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: a case of successful switch to an alternative ALK inhibitor and systematic review of the literature

Lung Cancer: Targets and Therapy, 2018
Lei Deng,1 Janaki Sharma,2 Elizabeth Ravera,2 Balazs Halmos,2 Haiying Cheng2 1Department of Medicine, Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, NY, USA; 2Department of Oncology, Montefiore Medical Center/Albert Einstein College of
Deng L, Sharma J, Ravera E, Halmos B, Cheng H   +4 more
doaj  

Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer

BACKGROUND: Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive non-small-cell lung cancer (NSCLC).
Pérol, M., Shaw, A. T., Golding, S., Ahn, Jin S., Camidge, D. ., Noe, J., Dziadziuszko, R., Peters, S., Gadgeel, S., Mitry, E., Mok, T., Ou, S. H. I., Balas, B., Morcos, P. N., Kim, D. ., Zeaiter, A., Rosell, R.   +16 more
core  

Alectinib Efficacy Post-Brigatinib Against Advanced ALK+ Non-Small Cell Lung Cancer (BrigALK2-GFPC 02-2019 Study)

BACKGROUND: Brigatinib and alectinib are next-generation anaplastic lymphoma kinase inhibitors (ALKis) showing efficacy against naïve and post-crizotinib-treated advanced ALK+ non-small-cell lung cancers (NSCLCs).
Cadranel, Jacques, Mennecier, Bertrand, Pérol, Maurice, Duruisseaux, Michael, Doubre, Helene, Descourt, Renaud, Greillier, Laurent, Culine, Stéphane, Bylicki, Olivier, Guisier, Florian, Chouaid, Christos   +10 more
core   +1 more source

Real-world safety profile of alectinib: a 10-year pharmacovigilance study based on the FDA adverse event reporting system. [PDF]

Front Med (Lausanne)
Zhang L, Li D, Luo C, Fan L, Hu M, Ye F, Gu P.   +6 more
europepmc   +1 more source

Chronic Myeloid Leukaemia Developing During Long-Term Alectinib Therapy Successfully Managed With Concomitant Nilotinib: A Case Report. [PDF]

Respirol Case Rep
Ikematsu Y, Izumi M, Wakamatsu K, Kawasaki M.   +3 more
europepmc   +1 more source

Correction: Case Report: Complete response and prolonged survival to alectinib in a NSCLC patient with metastases harboring a rare WDR43::ALK structural deletion. [PDF]

Front Oncol
Frontiers Production Office.
europepmc   +1 more source